SCHEMBL3602307

SCHEMBL3602307

CCOC(=O)C(C#N)=Cc1ccc(OC)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.70
PKM P14618 1/20 0.70
HTT P42858 1/20 0.70
MAPT P10636 8/20 0.69
KDM4E B2RXH2 5/20 0.69
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
SMN1; SMN2 Q16637 1/20 0.64
LMNA P02545 1/20 0.63
L3MBTL1 Q9Y468 2/20 0.62
NPC1 O15118 1/20 0.62
MAPK1 P28482 1/20 0.62
CASP3 P42574 1/20 0.62
RAB9A P51151 1/20 0.62
SENP8 Q96LD8 1/20 0.62
SENP7 Q9BQF6 1/20 0.62
SENP6 Q9GZR1 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
HPGD P15428 2/20 0.61
GAA P10253 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19988422 1.00 ALDH1A1 (0.70) ALDH1A1PKMHTTMAPTKDM4E
SCHEMBL3602305 1.00 ALDH1A1 (0.70) ALDH1A1PKMHTTMAPTKDM4E
SCHEMBL2139676 0.91 ALDH1A1 (0.81) ALDH1A1PKMHTTMAPTKDM4E
SCHEMBL2139678 0.91 ALDH1A1 (0.81) ALDH1A1PKMHTTMAPTKDM4E
SCHEMBL4317761 0.91 ALDH1A1 (0.81) ALDH1A1PKMHTTMAPTKDM4E
SCHEMBL19011313 0.90 ALDH1A1 (0.59) ALDH1A1PKMHTTMAPTKDM4E
SCHEMBL17329465 0.90 ALDH1A1 (0.71) ALDH1A1PKMHTTMAPTKDM4E
SCHEMBL15371840 0.90 ALDH1A1 (0.71) ALDH1A1PKMHTTMAPTKDM4E
SCHEMBL7866449 0.89 ALDH1A1 (0.64) ALDH1A1PKMHTTMAPTKDM4E
SCHEMBL7866447 0.89 ALDH1A1 (0.64) ALDH1A1PKMHTTMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118076133-A Composite material, composition, preparation method of composite material, light-emitting device and display device TCL科技集团股份有限公司 2024-05-24 CN claimed
CN-120136926-A Catalyst for condensation reaction of aldehyde and ethyl cyanoacetate Knoevenagel and preparation method thereof 河北松辰医药科技有限公司 2025-06-13 CN disclosed
CN-118076133-A Composite material, composition, preparation method of composite material, light-emitting device and display device TCL科技集团股份有限公司 2024-05-24 CN disclosed
EP-3553097-B1 COPOLYMER AND OPTICAL FILM USING SAME TOSOH CORP (JP) 2022-05-04 EP disclosed
CN-113999232-A MAT2A inhibitors 南京正大天晴制药有限公司 2022-02-01 CN disclosed
US-11225540-B2 Copolymer and optical film using same TOSOH CORPORATION (JP) 2022-01-18 US disclosed
CN-110248971-B Copolymer and optical film using the same 东曹株式会社 2021-11-02 CN disclosed
CN-113416191-A Method for synthesizing tricyclic framework 2-pyridone/2-pyridine imine compound 西安交通大学 2021-09-21 CN disclosed
US-20200095358-A1 COPOLYMER AND OPTICAL FILM USING SAME TOSOH CORPORATION (JP) 2020-03-26 US disclosed
EP-3553097-A1 COPOLYMER AND OPTICAL FILM USING SAME Tosoh Corporation (JP) 2019-10-16 EP disclosed
CN-109970655-A Out-phase basic catalyst and α based on the out-phase basic catalyst, β-unsaturated compound continuous flow preparation method 华侨大学 2019-07-05 CN disclosed
US-7947707-B2 Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-05-24 US disclosed
US-20100063080-A1 CXCR2 inhibitors PRESS NEIL JOHN 2010-03-11 US disclosed
US-20090306396-A1 NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2086947-A1 PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS Novartis AG (CH) 2009-08-12 EP disclosed
WO-2008061740-A1 PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2008-05-29 WO disclosed
EP-0901512-A1 DETERGENT COMPOSITION UNILEVER PLC (GB) 1999-03-17 EP disclosed
WO-1997044422-A1 DETERGENT COMPOSITION UNILEVER PLC (GB) 1997-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306396-A1 NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME XDH, CBR3, CBR1 ALDH1A1 280/4885PKM 2347/4885HTT 2813/4885
US-20100063080-A1 CXCR2 inhibitors CXCR2, CXCR1, CXCR3 ALDH1A1 931/4885PKM 4225/4885HTT 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.